ADMAADMA Biologics, Inc.
Is the price fair?
Undemanding: modest expectations priced in and cheap vs its sector.
Priced for ~4% a year FCF growth. The price demands less than its three-year revenue growth of 35% a year, expectations look modest.
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ADMA's price assumes
ADMA Biologics, Inc. trades at 14.8× earnings against 18.8× for the median Biotechnology name, cheaper than its own group.
Trailing P/E · Biotechnology median 18.8 · cheaper than the typical name in its group
- Price / sales
- 3.95
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 5.8%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- +3.8%
Growth the price implies · The price pays for +3.8% free cash flow growth a year for a decade; revenue has grown +35% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 4.95
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 9.27
- EV / salestoday's price, trailing year to Jun 30, 2026
- 4.06
- Healthcare median P/E509 names
- 26.2
- Biotechnology median P/E244 names
- 18.8
- Free cash flow, trailing twelve months
- $116M
- Market capitalisation
- $2.02B
- 3-year revenue growth
- +35%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.